

## Special Issue

# Diagnosis and Treatment of Malignant Bone Tumors

### Message from the Guest Editor

Malignant bone tumors require intensive treatments, including chemotherapy, surgical tumor excision, and radiation therapy. Although limb-salvage surgery is standard treatment for malignant bone tumors, there remains various problems such as limited options of anticancer agents, postoperative surgical site infections, breakage of tumor prosthesis, and fracture of transplanted bone. To improve oncological and functional outcomes of malignant bone tumors, improvement of diagnostic method, selection of appropriate anticancer drugs, development of new anticancer drugs, improvement of surgical techniques and implants, are demanded. This Special Issue of *Cancers* aims to bring together the highest quality original/review articles on clinical research for malignant bone tumors.

---

### Guest Editor

Dr. Shinji Miwa

Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/85107](https://mdpi.com/si/85107)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)